Skip to content
The Policy Vault
Methodology
Why
Contact
Coverage
/
Medica
/
Tafinlar (dabrafenib)
/
Solid Tumors
← Back
Tafinlar (dabrafenib) — Medica
Solid Tumors
Initial criteria
Patient has BRAF V600 mutation-positive disease
Medication will be taken in combination with Mekinist (trametinib tablets or oral solution)
Approval duration
1 year
